Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to confirm the efficacy, safety, and immunogenicity of
recombinant human C1 inhibitor (rhC1INH) at a dose of 50 U/kg when used for the treatment of
acute angioedema attacks in Hereditary Angioedema (HAE) patients.